The U.S. Food and Drug Administration (FDA) has approved BRIXADI, also known as buprenorphine, for people with moderate to severe opioid use disorder. The drug is an extended-release injection for subcutaneous use (CIII), meant to be taken weekly or monthly at a healthcare provider’s office. Brixadi is a form of Medication-Assisted Treatment meant to help
Everyone has had to adjust to life while facing the threat of COVID-19. While this health crisis rages on, so does the war against the opioid crisis. Some treatment centers have had to stop taking new patients in order to help flatten the curve of spread. So how are addicted persons getting help with medication-assisted
Medication-assisted Treatment (MAT) can be a lifeline for those who are addicted to opioids and struggle with long-term cravings and short-term withdrawal symptoms. However, research by NPR shows that doctors and pharmacists mistrust the drug, resulting in few people seeking help with addiction gaining access to it. Doctors Have Little Incentive to Prescribe Buprenorphine Buprenorphine,
This week, New York City Mayor Michael Bloomberg and Gov. Gina Raimondo's took a tour of the facilities for inmates and people involved in the post-incarceration program. Gov. Raimondo then participated in a roundtable discussion about the state's medication-assisted treatment program. Introduced in 2017, the program offers inmates in the prison system, also called AC)
The Food and Drug Administration is looking to expand medication-assisted opioid treatment, a type of treatment that often has a stigma attached to it due to being misunderstood. Much of this stigma is ill-suited, FDA Commissioner Scott Gottlieb told a U.S. House committee last Wednesday, and his agency is taking action to make these drugs
